mTOR and cancer: insights into a complex relationship

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells

Fei, S.-J., Zhang, X., Dong, S., Cheng, H., Yi-fang, Z., Huang, L., Zhou, H., Xie, Z., Chen, Z., & Wu, Y.-L. L. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069104 · Cited by 45

Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*

Murugan, A. K., Alzahrani, A. S., & Xing, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399485 · Cited by 47

Translational control of cyclins

Tarn, W., & Lai, M. (2011) · Cell Division · doi:10.1186/1747-1028-6-5 · Cited by 45

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets

Swanton, C., Larkin, J., Gerlinger, M., Eklund, A. C., Howell, M. T., Stamp, G., Downward, J., Gore, M. E., Futreal, P. A., Escudier, B. J., et al. (2010) · Genome Medicine · doi:10.1186/gm174 · Cited by 45

mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells

Silvera, D., Ernlund, A. W., Arju, R., Connolly, E. P., Volta, V., Wang, J., & Schneider, R. J. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00577-16 · Cited by 43

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

Burris, H. A., Kurkjian, C. D., Hart, L., Pant, S., Murphy, P. B., Jones, S. F., Neuwirth, R. B., Patel, C. G., Zohren, F., & Infante, J. R. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3343-4 · Cited by 45

MicroRNAs and Autophagy: Fine Players in the Control of Chondrocyte Homeostatic Activities in Osteoarthritis

D’Adamo, S., Cetrullo, S., Minguzzi, M., Silvestri, Y., Borzı̀, R. M., & Flamigni, F. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3720128 · Cited by 45

Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature

Murphy, J. D., Spalding, A. C., Somnay, Y. R., Markwart, S., Ray, M. E., & Hamstra, D. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1019 · Cited by 44

Parameters of protection against ultraviolet radiation‐induced skin cell damage

Cao, C., & Wan, Y. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21780 · Cited by 45

Mutation of the Rb1 Pathway Leads to Overexpression of mTor, Constitutive Phosphorylation of Akt on Serine 473, Resistance to Anoikis, and a Block in c-Raf Activation

El‐Naggar, S., Liu, Y., & Dean, D. C. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00197-09 · Cited by 44

Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme.

Albert, L., Karsy, M. J., Murali, R., & Jhanwar‐Uniyal, M. (2009) · PubMed · Cited by 44

Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo

Zou, Y., Ge, M., & Wang, X. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.052 · Cited by 44

Advancement in research and therapy of NF1 mutant malignant tumors

Tao, J., Sun, D., Dong, L., Zhu, H., & Hou, H. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01570-8 · Cited by 44

Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions

Wang, S., Wu, W., Lin, X., Zhang, K. M., Wu, Q., Luo, M., & Zhou, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01171-8 · Cited by 47

Characterization of the Rheb‐mTOR Signaling Pathway in Mammalian Cells: Constitutive Active Mutants of Rheb and mTOR

Sato, T., Umetsu, A., & Tamanoi, F. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)38021-x · Cited by 43

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

Khokhar, N. Z., Altman, J. K., & Platanias, L. C. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834b892d · Cited by 43

Disruption of PDGFRα-initiated PI3K activation and migration of somite derivatives leads to spina bifida

Pickett, E., Olsen, G. S., & Tallquist, M. D. (2008) · Development · doi:10.1242/dev.013763 · Cited by 43

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions

Villarreal-Garza, C. M., Cortés, J., André, F., & Verma, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mds075 · Cited by 44

TAK1 regulates autophagic cell death by suppressing the phosphorylation of p70 S6 kinase 1

Shin, J. H., Min, S. H., Kim, S., Kim, Y., Park, J., Lee, H. K., & Yoo, O. J. (2013) · Scientific Reports · doi:10.1038/srep01561 · Cited by 43

p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb

Agarwal, S., Bell, C. M., Taylor, S. M., & Moran, R. G. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0159 · Cited by 43

MHY1485 activates mTOR and protects osteoblasts from dexamethasone

Zhao, S., Chen, C., Wang, S., Ji, F., & Xie, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.104 · Cited by 43

miRNA Modulation and Antitumor Activity by the Extra-Virgin Olive Oil Polyphenol Oleacein in Human Melanoma Cells

Carpi, S., Polini, B., Manera, C., Digiacomo, M., Salsano, J. E., Macchia, M., Scoditti, E., & Nieri, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574317 · Cited by 44

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

Vemulapalli, S., Mita, A. C., Alvarado, Y., Sankhala, K. K., & Mita, M. M. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0179-4 · Cited by 42

Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary

Hisamatsu, T., Mabuchi, S., Matsumoto, Y., Kawano, M., Sasano, T., Takahashi, R., Sawada, K., Ito, K., Kurachi, H., Schilder, R. J., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1185 · Cited by 43

Expression of the Golgi phosphoprotein-3 gene in human gliomas: a pilot study

Li, X., Liu, W., Chen, S., Zhang, L.-Q., Li, X., & Wang, L. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0573-x · Cited by 42

Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells

Aleffi, S., Navari, N., Delogu, W., Galastri, S., Novo, E., Rombouts, K., Pinzani, M., Parola, M., & Marra, F. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00047.2010 · Cited by 42

Preclinical study of cinobufagin as a promising anti-colorectal cancer agent

Lu, X., Qiao, Y.-B., Li, Y., Yang, B., Chen, M., & Xing, C.-G. (2016) · Oncotarget · doi:10.18632/oncotarget.13519 · Cited by 42

mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs

David‐West, G., Ernlund, A. W., Gadi, A., & Schneider, R. J. (2018) · Oncotarget · doi:10.18632/oncotarget.25869 · Cited by 42

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib

Dhakal, A., Thomas, R. A., Levine, E. G., Brufsky, A., Takabe, K., Hanna, M. G., Attwood, K. M., Miller, A., Khoury, T., Early, A., et al. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420944864 · Cited by 42

Combined Inhibition of MEK and Mammalian Target of Rapamycin Abolishes Phosphorylation of Cyclin-Dependent Kinase 4 in Glioblastoma Cell Lines and Prevents Their Proliferation

Paternot, S., & Roger, P. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3260 · Cited by 42

Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer

Guigon, C. J., Fozzatti, L., Lu, C., Willingham, M. C., & Cheng, S.-Y. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq059 · Cited by 42

Treatment of Pediatric Low-Grade Gliomas

Sait, S. F., Giantini-Larsen, A., Tringale, K. R., Souweidane, M. M., & Karajannis, M. A. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01257-3 · Cited by 45

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Subbiah, V., Coleman, N., Piha-Paul, S. A., Tsimberidou, A. M., Jankú, F., Rodon, J. A., Pant, S., Dumbrava, E. E. I., Fu, S., Hong, D. S., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0260 · Cited by 42

Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy

Jeong, S., Woo, Chung, Jung, J., Ju, E. J., Kang, Lee, Seo, Lee, J. S., Lee, et al. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29480 · Cited by 41

Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity

Liu, P., Guo, J., Gan, W., & Wei, W. (2014) · Protein & Cell · doi:10.1007/s13238-014-0021-8 · Cited by 45

Pten regulates collective cell migration during specification of the anterior–posterior axis of the mouse embryo

Bloomekatz, J. E., Grego‐Bessa, J., Migeotte, I., & Anderson, K. V. (2012) · Developmental Biology · doi:10.1016/j.ydbio.2012.02.005 · Cited by 44

Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma

Darwish, O. M., Kapur, P., Youssef, R. F., Bagrodia, A., Belsante, M., Alhalabi, F., Sagalowsky, A. I., Lotan, Y., & Margulis, V. (2013) · Urology · doi:10.1016/j.urology.2012.11.030 · Cited by 41

Intra-articular injection of Torin 1 reduces degeneration of articular cartilage in a rabbit osteoarthritis model

Cheng, N.-T., Guo, A., & Cui, Y.-P. (2016) · Bone and Joint Research · doi:10.1302/2046-3758.56.bjr-2015-0001 · Cited by 41

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer

Biersack, B., Nitzsche, B., & Höpfner, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.105 · Cited by 42

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis

Aldin, A., Besiroglu, B., Adams, A., Monsef, I., Piechotta, V., Tomlinson, E., Hornbach, C., Dressen, N., Goldkuhle, M., Maisch, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013798.pub2 · Cited by 40

Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease

Brown, V. I., Seif, A. E., Reid, G. S. D., Teachey, D. T., & Grupp, S. A. (2008) · Immunologic Research · doi:10.1007/s12026-008-8038-9 · Cited by 41

Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study

Márk, Á., Hajdú, M., Váradi, Z., Sticz, T. B., Nagy, N., Csomor, J., Berczi, L., Varga, V., Csóka, M., Kopper, L., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-250 · Cited by 41

Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas

Johnson, M. D., O’Connell, M., Vito, F., & Bakos, R. S. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9746-7 · Cited by 41

Signal Transducer and Activator of Transcription 3 Is Required for Abnormal Proliferation and Survival of TSC2-Deficient Cells: Relevance to Pulmonary Lymphangioleiomyomatosis

Goncharova, E. A., Goncharov, D. A., Damera, G., Tliba, O., Amrani, Y., Panettieri, R. A., & Krymskaya, V. P. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.057042 · Cited by 41

Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer

Litzenburger, B. C., & Brown, P. H. (2014) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0144-1 · Cited by 41

mTOR function in skeletal muscle: a focal point for overnutrition and exercise

Rivas, D. A., Lessard, S. J., & Coffey, V. G. (2009) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h09-073 · Cited by 39

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

Ogita, S., & LoRusso, P. M. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0176-7 · Cited by 40

Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma

Li, S.-H., Chen, C.-H., Lu, H.-I., Huang, W., Tien, W.-Y., Lan, Y.-C., Lee, C.-C., Chen, Y.-H., Huang, H.-Y., Chang, A. Y., et al. (2014) · Surgery · doi:10.1016/j.surg.2014.10.014 · Cited by 41

Signal-dependent regulation of gene expression as a target for cancer treatment: Inhibiting p38α in colorectal tumors

Chiacchiera, F., & Simone, C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.061 · Cited by 41

Protein kinase Cζ exhibits constitutive phosphorylation and phosphatidylinositol-3,4,5-triphosphate-independent regulation

Tobias, I. S., Kaulich, M., Kim, P. K., Simon, N., Jacinto, E., Dowdy, S., King, C., & Newton, A. (2015) · Biochemical Journal · doi:10.1042/bj20151013 · Cited by 39

mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model

Callejas‐Valera, J. L., Iglesias‐Bartolomé, R., Amornphimoltham, P., Palacios‐García, J., Martı́n, D., Califano, J. A., Molinolo, A., & Gutkind, J. S. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw086 · Cited by 40

Everolimus is a new anti-cancer molecule: Metabolic side effects as lipid disorders and hyperglycemia

Morviducci, L., Rota, F., Rizzà, L., Giacinto, P. D., Ramponi, S., Nardone, M. R., Tubili, C., Lenzi, A., Zuppi, P., & Baldelli, R. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.001 · Cited by 40

Analysis of the regulatory motifs in eukaryotic initiation factor 4E‐binding protein 1

Lee, V. H.-Y., Healy, T. M., Fonseca, B. D., Hayashi, A. A., & Proud, C. G. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06372.x · Cited by 41

Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging

Zhuo, L., Cai, G., Liu, F., Fu, B., Liu, W., Hong, Q., Ma, Q., Peng, Y., Wang, J., & Chen, X. (2009) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2009.08.005 · Cited by 40

Insulin-Like Growth Factors and Insulin: At the Crossroad Between Tumor Development and Longevity

Novosyadlyy, R., & LeRoith, D. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls065 · Cited by 41

Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia

Kościuczuk, E. M., Saleiro, D., & Platanias, L. C. (2016) · Cytokine · doi:10.1016/j.cyto.2016.01.024 · Cited by 40

The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer

Wittig, R., & Coy, J. F. (2007) · Perspectives in Medicinal Chemistry · doi:10.1177/1177391x0700100006 · Cited by 58

The role of glutamine in neurogenesis promoted by the green tea amino acid theanine in neural progenitor cells for brain health

Yoneda, Y., Kuramoto, N., & Kawada, K. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104505 · Cited by 39

Regulation between survival, persistence, and elimination of intracellular mycobacteria: a nested equilibrium of delicate balances

Kumar, D., & Rao, K. V. S. (2010) · Microbes and Infection · doi:10.1016/j.micinf.2010.10.009 · Cited by 39

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy

Tan, J. Y., & Yu, Q. (2013) · 癌症：英文版 · doi:10.5732/cjc.012.10287 · Cited by 39

Targeting pancreatic cancer stem cells for cancer therapy

Xia, J., Chen, C., Chen, Z., Miele, L., Sarkar, F. H., & Wang, Z. P. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.002 · Cited by 39

Photodynamic Therapy Targets the mTOR Signaling Network in Vitro and in Vivo

Weyergang, A., Berg, K., Kaalhus, O., Peng, Q., & Selbo, P. K. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800156e · Cited by 39

Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

Xu, D.-Z., Geng, Q.-R., Tian, Y., Cai, M.-Y., Fang, X.-J., Zhan, Y. Q., Zhou, Z.-W., Li, W., Chen, Y.-B., Sun, X., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-536 · Cited by 38

Immunohistochemical Expression of Phospho-mTOR Is Associated With Poor Prognosis in Patients With Gallbladder Adenocarcinoma

Leal, P., García, P., Sandoval, A., Letelier, P. J., Brebi, P., Ili, C., Álvarez, H., Tapia, Ó., & Roa, J. C. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0032-oa · Cited by 39

New molecular targets in malignant gliomas

de Groot, J., & Gilbert, M. R. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282f15650 · Cited by 39

Anaplastic Lymphoma Kinase (ALK)-Induced Malignancies: Novel Mechanisms of Cell Transformation and Potential Therapeutic Approaches

Wasik, M. A., Zhang, Q., Marzec, M., Kasprzycka, M., Wang, H. Y., & Liu, X. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.02.007 · Cited by 41

Genome-scale RNAi on living-cell microarrays identifies novel regulators ofDrosophila melanogasterTORC1–S6K pathway signalingPreprint

Lindquist, R. A., Ottina, K. A., Wheeler, D. B., Hsu, P. P., Thoreen, C. C., Guertin, D. A., Ali, S. M., Sengupta, S., Shaul, Y. D., Lamprecht, M. R., et al. (2011) · Genome Research · doi:10.1101/gr.111492.110 · Cited by 38

Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions

Blagosklonny, M. V. (2012) · Oncotarget · doi:10.18632/oncotarget.890 · Cited by 38

GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors

Thorne, C. A., Wichaidit, C., Coster, A. D., Posner, B. A., Wu, L. F., & Altschuler, S. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1690 · Cited by 40

Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer

Geuna, E., Milani, A., Martinello, R., Aversa, C., Valabrega, G., Scaltriti, M., & Montemurro, F. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1008132 · Cited by 39

IKK interacts with rictor and regulates mTORC2

Xu, Y., Lai, E.-Y., Liu, J., Lin, J., Yang, C., Jia, C., Li, Y., Bai, X., & Li, M. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.07.008 · Cited by 38

The Identity and Fate Decision Control of Spermatogonial Stem Cells

Nagano, M. C., & Yeh, J. R. (2012) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-416024-8.00003-9 · Cited by 38

microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells

Cui, Y., Zhao, J., Yi, L., & Jiang, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156915 · Cited by 38

Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway

Zhu, X., Chu, H., Jiang, S., Liu, Q., Liu, L., Xue, Y., Zheng, S., Wan, W., Qiu, J., Wang, J., et al. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.04.013 · Cited by 37

Targeting PP2A activates AMPK signaling to inhibit colorectal cancer cells

Dai, C., Zhang, X., Xie, D., Tang, P., Li, C., Zuo, Y., Jiang, B., & Xue, C. (2017) · Oncotarget · doi:10.18632/oncotarget.21336 · Cited by 38

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer

Thomas, J. V., & Sonpavde, G. (2022) · Cancers · doi:10.3390/cancers14071795 · Cited by 41

p73 as a Pharmaceutical Target for Cancer Therapy

Bisso, A., Collavin, L., & Sal, G. D. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222667 · Cited by 41

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas

Eroglu, Z., Tawbi, H. A., Hu, J. S., Guan, M., Frankel, P. H., Ruel, N. H., Wilczynski, S. P., Christensen, S. M., Gandara, D. R., & Chow, W. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.126 · Cited by 38

Amino acids and insulin are regulators of muscle protein synthesis in neonatal pigs

Davis, T. A., Suryawan, A., Orellana, R. A., Fiorotto, M. L., & Burrin, D. G. (2010) · animal · doi:10.1017/s1751731110000984 · Cited by 38

The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker

Knoll, M., Macher‐Goeppinger, S., Kopitz, J., Duensing, S. M., Pahernik, S. A., Hohenfellner, M., Schirmacher, P., & Roth, W. (2015) · Oncotarget · doi:10.18632/oncotarget.6225 · Cited by 38

Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin

Ampuero, J. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1105 · Cited by 38

Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates

Simpson, L., & Galanis, E. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.11.1593 · Cited by 38

High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma

Anagnostou, V., Bepler, G., Syrigos, K. N., Tanoue, L. T., Gettinger, S. N., Homer, R., Boffa, D. J., Detterbeck, F. C., & Rimm, D. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0099 · Cited by 37

Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease

Wu, M., Arcaro, A., Varga, Z., Vogetseder, A., Hir, M. L., Wuthrich, R. P., & Serra, A. L. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00430.2009 · Cited by 38

Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation

Chen, M., Liu, Y.-Y., Xing, Z., Zhang, Z.-Q., Jiang, Q. L., Lu, P., & Cao, C. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1094 · Cited by 38

The Roles of Post-Translational Modifications on mTOR Signaling

Yin, S., Liu, L., & Gan, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041784 · Cited by 39

A High-Throughput, Cell-Based Screening Method for siRNA and Small Molecule Inhibitors of mTORC1 Signaling Using the In Cell Western Technique

Hoffman, G. R., Moerke, N. J., Hsia, M., Shamu, C. E., & Blenis, J. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2009.0213 · Cited by 37

Phospholipases D1 and D2 Suppress Appetite and Protect against Overweight

Viera, J. T., El‐Merahbi, R., Nieswandt, B., Stegner, D., & Sumara, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157607 · Cited by 37

Nitrous Oxide, a Rapid Antidepressant, Has Ketamine-like Effects on Excitatory Transmission in the Adult Hippocampus

Izumi, Y., Hsu, F., Conway, C. R., Nägele, P., Mennerick, S. J., & Zorumski, C. F. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.06.016 · Cited by 35

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib

Coppin, C. (2010) · Biologics · doi:10.2147/btt.s6748 · Cited by 36

Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science

Porta, C., Sabbatini, R., Procopio, G., Paglino, C., Galligioni, E., & Ortega, C. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.81 · Cited by 36

Targeting AMPK in the treatment of malignancies

Vakana, E., Altman, J. K., & Platanias, L. C. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23369 · Cited by 37

Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study

Park, S. J., Lee, T. J., & Chang, I. H. (2011) · Korean journal of urology · doi:10.4111/kju.2011.52.7.466 · Cited by 36

Rapamycin down-regulates LDL-receptor expression independently of SREBP-2

Sharpe, L. J., & Brown, A. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.06.108 · Cited by 36

The Emerging Role of Large Immunophilin FK506 Binding Protein 51 in Cancer

Romano, S., Sorrentino, A., Pace, A. L. D., Nappo, G., Mercogliano, C. J., & Romano, M. F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711798194333 · Cited by 36

Systemic Therapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future

Giglia, J. L., Antonia, S. J., Berk, L. B., Bruno, S., Dessureault, S., & Finkelstein, S. E. (2010) · Cancer Control · doi:10.1177/107327481001700207 · Cited by 36

Comparative transcriptomic analysis of skeletal muscle tissue during prenatal stages in Tongcheng and Yorkshire pig using RNA-seq

Liu, H., Xi, Y., Liu, G., Zhao, Y., Li, J., & Lei, M. (2018) · Functional & Integrative Genomics · doi:10.1007/s10142-017-0584-6 · Cited by 37

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77

TOR (target of rapamycin) as an anti-cancer target

Bousquet, G., Dreyer, C., Faivre, S. J., & Raymond, É. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.04.004 · Cited by 2

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies

Mehta, D., Rajput, K., Jain, D., Bajaj, A., & Dasgupta, U. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00530 · Cited by 25